Gregory Winter

Sir Gregory Paul Winter CBE FRS FMedSci (born 14 April 1951)[6][7] is a Nobel Prize-winning British molecular biologist best known for his work on the therapeutic use of monoclonal antibodies.

[6][14][15][16][17][18] For these developments Winter was awarded the 2018 Nobel Prize in Chemistry along with George Smith and Frances Arnold.

He was awarded a PhD degree, from the MRC Laboratory of Molecular Biology, for research on the amino acid sequence of tryptophanyl tRNA synthetase from the bacterium Bacillus stearothermophilus in 1977[23] supervised by Brian S.

[24] Later, Winter completed a term of post-doctoral fellowship at Imperial College London, and another at the Institute of genetics in University of Cambridge.

[26][27] He continued to specialise in protein and nucleic acid sequencing and became a Group Leader at the MRC Laboratory of Molecular Biology in 1981.

Georges J. F. Köhler and César Milstein had won the 1984 Nobel Prize for their work at the Laboratory of Molecular Biology, in discovering a method to isolate and reproduce individual, or monoclonal, antibodies from among the multitude of different antibody proteins that the immune system makes to seek and destroy foreign invaders attacking the body.

Winter was formerly the Joint Head of the Division of Protein and Nucleic acid Chemistry-Biotechnology, and was Deputy Director,[43] at the Laboratory of Molecular Biology, Cambridge, an institution funded by the UK Medical Research Council.

He was also Deputy Director of the MRC's Centre for Protein Engineering until its absorption into the Laboratory of Molecular Biology.

Greg Winter during Nobel press conference in Stockholm, December 2018